Barc Global Central Laboratory, Ghent, Belgium, and Diag2Tec, Montpellier, France, have signed a strategic cooperation agreement to market services around hematological cancers and, specifically, multiple myeloma.
The services seek to enable pharmaceutical and biotechnology companies to accelerate the optimization of future medicines, both for preclinical and clinical development, to improve the cost-efficiency of future drug development, and to accelerate “fast-track approval” and time to market.
Diag2Tec brings to the partnership expertise and know-how of the disease, including 40 human multiple myeloma cell lines that cover the range of heterogeneity of the disease, tools to assess drug efficacy and characterize mechanism of action, tools to predict resistance mechanisms and development of biomarkers, and companion diagnostics that serve as predictive signatures for the sensitivity of patient cells to a given drug. Barc provides its expertise in the development of clinical trials.
Michel Abiteboul, Barc.
“I am delighted to start this partnership with the Diag2Tec team, which has demonstrated a real expertise in multiple myeloma, with innovative and unique tools and services for fast and high-quality clinical studies.” says Michel Abiteboul, CEO of Barc. “As time is critical, it is essential to speed up the transition from preclinical to clinical development. The scope of our combined expertise and the quality of our resources allow us to offer a range of services that will effectively benefit our clients.”
Pierre Vidal, Diag2Tec.
“This partnership with Barc is a tremendous opportunity for us,” adds Pierre Vidal, CEO of Diag2Tec. “Their high-quality clinical development services perfectly complement our expertise and services. By working hand in hand with Barc, we are able to offer our customers the information needed to ensure high-quality clinical trials while optimizing their translational approach.”
